Calcium Hydroxylapatite for Receding Gums and Tooth Sensitivity
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores the use of calcium hydroxylapatite (CaHA) injections to treat receding gums and tooth sensitivity. The aim is to determine if these injections can improve gum health and reduce discomfort from sensitive teeth caused by exposed roots. Suitable candidates for this trial have mild to moderate gum recession, no active gum disease, and experience tooth sensitivity. As an unphased trial, participants contribute to innovative research that may lead to new solutions for gum health and tooth sensitivity.
Do I need to stop my current medications for the trial?
If you are taking medications that increase the risk of bleeding, like antiplatelet therapy, anticoagulants, or aspirin, you will need to stop them for a 7-day period before joining the trial. For other medications, the protocol does not specify if you need to stop them.
What prior data suggests that calcium hydroxylapatite is safe for treating receding gums and tooth sensitivity?
Research shows that calcium hydroxylapatite (CaHA) helps with receding gums and sensitive teeth. Studies have found that CaHA is usually well-tolerated in dental treatments, with no major safety concerns reported by participants. However, individuals with a history of allergic reactions to dental materials should exercise caution. Overall, past research suggests the treatment is safe, but individual experiences may vary.12345
Why are researchers excited about this trial?
Unlike standard treatments for receding gums and tooth sensitivity, such as scaling, root planing, or gum grafts, Calcium Hydroxylapatite offers a unique approach by using targeted injections. Researchers are excited because this treatment involves injecting Radiesse+, a formulation of Calcium Hydroxylapatite, directly into areas around the teeth. This technique potentially provides a more direct and less invasive way to rebuild gum tissue and reduce sensitivity, offering a novel mechanism to enhance gum health and comfort.
What evidence suggests that calcium hydroxylapatite is effective for receding gums and tooth sensitivity?
Research has shown that calcium hydroxylapatite (CaHA), which participants in this trial will receive, can effectively address receding gums and tooth sensitivity. One study demonstrated that CaHA improved gum recession for up to 12 months. Another study found that it significantly reduced tooth sensitivity, with patients reporting less tooth pain after receiving a CaHA injection. These findings suggest that CaHA could be a promising option for enhancing gum health and reducing tooth pain.12367
Who Is on the Research Team?
Dr. Louis Malcmacher, DMD
Principal Investigator
American Academy of Facial Esthetics
Are You a Good Fit for This Trial?
This trial is for individuals with gum recession and tooth hypersensitivity. Participants should not have a history of allergic reactions to dental materials, specifically calcium hydroxylapatite (CaHA).Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Radiesse(+) injections to treat gingival recession and hypersensitivity
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Calcium Hydroxylapatite
Find a Clinic Near You
Who Is Running the Clinical Trial?
American Academy of Facial Esthetics
Lead Sponsor
Merz North America, Inc.
Industry Sponsor
Leonard Paolillo
Merz North America, Inc.
Chief Executive Officer
Bachelor of Science in Business Administration from Manhattan College
Dr. McKinnon
Merz North America, Inc.
Chief Medical Officer since 2024
Ph.D. in Pharmacology and Toxicology from the University of Western Ontario